Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Plus Therapeutics Inc (PSTV)

Plus Therapeutics Inc (PSTV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 82,018
  • Shares Outstanding, K 137,429
  • Annual Sales, $ 5,820 K
  • Annual Income, $ -12,980 K
  • EBIT $ -13 M
  • EBITDA $ -13 M
  • 60-Month Beta 0.82
  • Price/Sales 13.92
  • Price/Cash Flow N/A
  • Price/Book 16.04
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.28
  • Most Recent Earnings $-0.04 on 10/30/25
  • Next Earnings Date 11/13/25
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.03
  • Number of Estimates 2
  • High Estimate -0.03
  • Low Estimate -0.03
  • Prior Year -0.67
  • Growth Rate Est. (year over year) +95.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4559 +43.67%
on 11/17/25
0.6600 -0.76%
on 12/04/25
+0.1457 (+28.61%)
since 11/04/25
3-Month
0.3875 +69.03%
on 09/24/25
0.9370 -30.10%
on 10/06/25
+0.2053 (+45.65%)
since 09/04/25
52-Week
0.1634 +300.86%
on 06/18/25
2.3099 -71.64%
on 03/07/25
-0.6750 (-50.75%)
since 12/04/24

Most Recent Stories

More News
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting

Cohort 1 data from multiple dose ReSPECT- Leptomeningeal Metastases (LM) trial showed no dosage limiting toxicity ReSPECT-Glioblastoma (GBM) trial of REYOBIQ as a novel therapeutic for recurrent...

PSTV : 0.6550 (+9.75%)
Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium

HOUSTON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...

PSTV : 0.6550 (+9.75%)
Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases

HOUSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals...

PSTV : 0.6550 (+9.75%)
Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

HOUSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of  Plus Therapeutics, Inc.  (Nasdaq:  PSTV ) (“Plus” or the “Company”), announced today that...

PSTV : 0.6550 (+9.75%)
HUM : 253.02 (-1.52%)
Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0

HOUSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...

PSTV : 0.6550 (+9.75%)
Plus: Q3 Earnings Snapshot

Plus: Q3 Earnings Snapshot

PSTV : 0.6550 (+9.75%)
Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights

US market introduction of the CNSide® CSF diagnostics platform, with first national coverage agreement with UnitedHealthcare Presented positive RESPECT-LM Ph1 clinical trial results HOUSTON,...

PSTV : 0.6550 (+9.75%)
Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch

Expands commercial readiness and diagnostic, manufacturing footprint Appoints new leadership in commercial strategy and technical operations HOUSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Plus...

PSTV : 0.6550 (+9.75%)
Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of  Plus Therapeutics, Inc.  (Nasdaq:  PSTV ) (“Plus” or the “Company”), announced today that...

PSTV : 0.6550 (+9.75%)
UNH : 333.49 (-1.83%)
Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT   

Non-dilutive payment is part of $17.6 million award granted for the Company’s leptomeningeal cancer targeted radiotherapeutic development program HOUSTON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Plus...

PSTV : 0.6550 (+9.75%)

Business Summary

Plus Therapeutics Inc. is a clinical-stage pharmaceutical company. It engages in developing treatments for cancer and other diseases primarily in the United States. The company's product candidate consists of DocePLUS which are in clinical stage. Plus Therapeutics Inc., formerly known as Cytori Therapeutics...

See More

Key Turning Points

3rd Resistance Point 0.7369
2nd Resistance Point 0.6985
1st Resistance Point 0.6767
Last Price 0.6550
1st Support Level 0.6165
2nd Support Level 0.5781
3rd Support Level 0.5563

See More

52-Week High 2.3099
Fibonacci 61.8% 1.4899
Fibonacci 50% 1.2366
Fibonacci 38.2% 0.9834
Last Price 0.6550
52-Week Low 0.1634

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar